- Theratechnologies Inc THTX reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed the consensus of $19.66 million.
- Trogarzo sales declined 8% to $6.63 million on lower unit sales as patients refrained from visiting their physicians. Competitive pressures and higher rebates also impacted the sales.
- It posted a net loss of $(0.10) for the quarter compared to $(0.09) a year ago, missing the consensus loss of $(0.07).
- The Company used $(3.13) million in operating cash flow.
- Price Action: THTX shares closed lower by 0.14% at $3.50 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
